Abcam, ab190886, Anti-N6-methyladenosine (m6A) antibody [mAbcam 190886] - BSA and Azide free

Size: 100µg
Rabbit Recombinant Monoclonal N6-methyladenosine (m6A) antibody. Carrier free. Suitable for Nucleotide Array and reacts with Modified Nucleic Acid samples. Cited in 16 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:mAbcam 190886,
Isotype:IgG,
Carrier free:Yes,
Applications:Nucleotide ArraySee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
N6-methyladenosine (m6A) is a post-transcriptional modification of RNA. m6A modification has been identified in all classes of RNA (rRNA, tRNA and mRNA) and is catalysed by an evolutionary conserved multi-subunit enzyme, methyltransferase like 3 (METTL3). Cellular and viral RNA has been known to be methylated for decades. Recent studies have found that mRNA is predominately m6A modified at stop codons and long internal exons, which are conserved between mouse and human. Emerging evidence suggests m6A plays an important role in regulating gene expression, alternative splicing patterns, downstream signalling (p53) as well as apoptosis.
The regulation of m6A modifications in mRNA has been linked to disease, where fat mass and obesity-associated (FTO) has been has been reported to be a obesity risk gene. FTO is a m6A demethylase and polymorphisms that result in increased FTO expression are associated with increased body mass and risk of obesity.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
N6-methyladenosine (m6A) is a chemical modification present in RNA molecules specifically marking the adenosine base with a methyl group at the nitrogen-6 position. This modification weighing approximately 14 Da occurs in diverse eukaryotic species and influences RNA metabolism. m6A methylation can be detected using techniques like m6A dots blot or m6A ELISA. The modification is abundant in tissues like the brain and testis reflecting its critical role in varying cell types. Also m6A is known as a dynamic and reversible mark with its levels continuously adjusted by enzymes called writers (methyltransferases) erasers (demethylases) and readers (RNA-binding proteins).
Biological function summary
M6A methylation affects mRNA processing stability translation and decay. It integrates into large multi-protein complexes where it influences gene expression outcomes by affecting the RNA's interaction with the cellular machinery. This methylation modification acts as a regulatory signal that influences essential processes such as cell differentiation and circadian rhythms. Elucidating the biological functions of m6A involves studying how it affects RNA fate and its downstream gene regulatory networks.
Pathways
M6A modification is central to the mRNA metabolic pathway and the PI3K-Akt signaling pathway. It interacts with various proteins such as METTL3 an m6A methyltransferase which is vital for mediating m6A modification. It also interacts with YTH domain-containing proteins that recognize m6A marks influencing transcript dynamics and gene expression. The interplay of m6A with proteins in these pathways underlines its role in fine-tuning cellular processes and responses.
M6A modification has a significant impact on cancer and neurological disorders. In cancers alterations in m6A methylation patterns can promote oncogenic transformation and metastasis. m6A-related proteins such as FTO an m6A demethylase have shown connections to these pathways affecting cancer progression. In neurological disorders m6A impacts aspects of neural development and function and abnormalities in its regulation may contribute to diseases like Alzheimer's. Understanding the roles of m6A in diverse diseases can pave the way for novel therapeutic approaches.